- Home
- APDN vs KZIA Comparison
APDN vs KZIA Comparison
Compare APDN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APDN
- KZIA
- Stock Information
- Founded
- APDN 1983
- KZIA 1994
- Country
- APDN United States
- KZIA Australia
- Employees
- APDN N/A
- KZIA N/A
- Industry
- APDN Other Consumer Services
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- APDN Consumer Discretionary
- KZIA Health Care
- Exchange
- APDN Nasdaq
- KZIA Nasdaq
- Market Cap
- APDN 894.1K
- KZIA 860.8K
- IPO Year
- APDN N/A
- KZIA 1999
- Fundamental
- Price
- APDN $0.67
- KZIA $3.59
- Analyst Decision
- APDN Strong Buy
- KZIA Strong Buy
- Analyst Count
- APDN 1
- KZIA 2
- Target Price
- APDN $75.00
- KZIA $57.50
- AVG Volume (30 Days)
- APDN 551.6K
- KZIA 37.5K
- Earning Date
- APDN 05-15-2025
- KZIA 05-23-2025
- Dividend Yield
- APDN N/A
- KZIA N/A
- EPS Growth
- APDN N/A
- KZIA N/A
- EPS
- APDN N/A
- KZIA N/A
- Revenue
- APDN $3,736,873.00
- KZIA $1,655,324.00
- Revenue This Year
- APDN $57.08
- KZIA N/A
- Revenue Next Year
- APDN $40.00
- KZIA N/A
- P/E Ratio
- APDN N/A
- KZIA N/A
- Revenue Growth
- APDN N/A
- KZIA 248000.00
- 52 Week Low
- APDN $0.72
- KZIA $2.86
- 52 Week High
- APDN $236.00
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- APDN 22.89
- KZIA 48.54
- Support Level
- APDN $0.78
- KZIA $3.22
- Resistance Level
- APDN $0.85
- KZIA $3.84
- Average True Range (ATR)
- APDN 0.06
- KZIA 0.35
- MACD
- APDN 0.09
- KZIA 0.05
- Stochastic Oscillator
- APDN 13.33
- KZIA 43.90
About APDN Applied DNA Sciences Inc.
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.